This study is in progress, not accepting new patients
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
a study on Prostate Cancer
Prostate Cancer, Non-Metastatic, Rising PSA, Castration-Resistant, Treatment-Naive, Post-abiraterone, Prostatic Neoplasms, ARN-509 (Phase 1), ARN-509 (Phase 2)
Lead Scientist at UCSF
- Rahul Aggarwal
I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Aragon Pharmaceuticals, Inc.
- Phase 1/2 Prostate Cancer Research Study
- Study Type
- About 127 people participating
- Last Updated